Blocking FGF23 signaling improves the growth plate of mice with X-linked hypophosphatemia
Journal of Endocrinology · 2023
DOI: 10.1530/joe-23-0025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Endocrinology, 2023. Verfasst von Rocío Fuente und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Physiology, University of Zurich, and National Center of Competence in Research NNCR Kidney, Zurich, CH, Switzerland. Hauptthemen laut MEDLINE: Familial Hypophosphatemic Rickets, Growth Plate. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
Fibroblast growth factor 23 (FGF23) is a phosphaturic hormone. X-linked hypophosphatemia (XLH) is the most prevalent inherited phosphate wasting disorder due to mutations in the PHEX gene, which cause elevated circulating FGF23 levels. Clinically, it is characterized by growth impairment and defective mineralization of bones and teeth. Treatment of XLH is challenging. Since 2018, neutralizing antibodies against FGF23 have dramatically improved the therapy of XLH patients, although not all patients fully respond to the treatment, and it is very costly. C-terminal fragments of FGF23 have recently emerged as blockers of intact FGF23 signaling. Here, we analyzed the effect on growth and bone of a short 26 residues long C-terminal FGF23 (cFGF23) fragment and two N-acetylated and C-amidated cFGF23 peptides using young XLH mice ( Phex C733RMhda mice). Although no major changes in blood parameters were observed after 7 days of treatment with these peptides, bone length and growth plate structure improved. The modified peptides accelerated the growth rate probably by improving growth plate structure and dynamics. The processes of chondrocyte proliferation, death, hypertrophy, and the cartilaginous composition in the growth plate were partially improved in young treated XLH mice. In conclusion, these findings contribute to understand the role of FGF23 signaling in growth plate metabolism and show that this may occur despite continuous hypophosphatemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Physiology, University of Zurich, and National Center of Competence in Research NNCR Kidney, Zurich, CH, Switzerland.
- Division of Pediatrics, University of Oviedo, Oviedo, Spain.
- Department of Pediatrics, Hospital Universitario Central, Oviedo, Spain.
- AO Research Institute Davos, AO Foundation, Clavadelerstrasse, Davos Platz, Switzerland.
ORCID-Profile: Isabel Rubio-Aliaga
Zitieren
APA
Fuente, R., Pastor-Arroyo, E. M., Gehring, N., Oro Carbajosa, P., Alonso-Durán, L., Zderic, I., Tapia-Dean, J., Hamid, A. K., Bettoni, C., Santos, F., Wagner, C. A., & Rubio-Aliaga, I. (2023). Blocking FGF23 signaling improves the growth plate of mice with X-linked hypophosphatemia. Journal of Endocrinology. https://doi.org/10.1530/joe-23-0025
Vancouver
Fuente R, Pastor-Arroyo EM, Gehring N, Oro Carbajosa P, Alonso-Durán L, Zderic I, et al. Blocking FGF23 signaling improves the growth plate of mice with X-linked hypophosphatemia. Journal of Endocrinology. 2023. doi:10.1530/joe-23-0025
BibTeX
@article{Fuente2023,
author = {Fuente, Rocío and Pastor-Arroyo, Eva-Maria and Gehring, Nicole and Oro Carbajosa, Patricia and Alonso-Durán, Laura and Zderic, Ivan and Tapia-Dean, James and Hamid, Ahmad Kamal and Bettoni, Carla and Santos, Fernando and Wagner, Carsten A and Rubio-Aliaga, Isabel},
title = {Blocking FGF23 signaling improves the growth plate of mice with X-linked hypophosphatemia},
journal = {Journal of Endocrinology},
year = {2023},
doi = {10.1530/joe-23-0025}
}
EUVIMED